Halozyme Therapeutics announced that the company is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47 percent in premarket trading on April 13.
Sanofi plans to list the company’s drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.
Mike Hidock, Director of Quality and Compliance Services at IQVIA, analyzes key considerations for preparing quality management systems (QMS) for fast tracked COVID-19 treatment approvals.
As the fraud trial of Theranos founder Elizabeth Holmes headlines the pharma legal news, other court-related cases are taking place, including a ruling in the legal spat between Takeda and AbbVie over a supply agreement for the prostate cancer drug Lupron.
North Carolina’s life sciences ecosystem continues to expand as Amgen announced plans to build a new $550 million biologics manufacturing center in Holly Springs in the Research Triangle Park area.
The Takeda Pharmaceutical Co.-led group that is developing a blood plasma treatment for Covid-19 started manufacturing while the late-stage trial to determine whether the hyperimmune globulin therapy works is ongoing, Chief Executive Christophe Weber said.
AstraZeneca filed a Worker Readjustment and Retraining Notification Act (WARN) notice with the State of Colorado, indicating plans to lay off 210 people in Boulder and Longmont.
Switzerland-based Roche AG is tweaking its operations. The latest is an announcement that the company plans to eliminate 75 jobs in central Massachusetts.
Sanofi plans to invest $673 million annually over the next two to three years in biologics production.
Novartis AG is shaking up its operations by terminating approximately 500 production and development positions in Switzerland, but adding an additional 350 jobs to its growing biotech business, Matthias Leuenberger said in a posting on the company’s Swiss site.